Information Provided By:
Fly News Breaks for February 16, 2016
ALNY
Feb 16, 2016 | 08:09 EDT
Leerink analyst Michael Schmidt lowered his price target for Alnylam Pharmaceuticals to $120 after the company reported Q4 results and provided pipeline updates. The company continues to execute on its genetic medicine programs while adding cardio-metabolic and infectious disease programs, Schmidt tells investors in a research note. His new price target reflects reduced valuation multiples in the sector and higher spending assumptions. Schmidt keeps an Outperform rating on the name.
News For ALNY From the Last 2 Days
There are no results for your query ALNY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.